Thrombin–aptamer recognition: a revealed ambiguity by Russo Krauss, Irene et al.
Thrombin–aptamer recognition: a revealed ambiguity
Irene Russo Krauss
1, Antonello Merlino
1,2, Concetta Giancola
1, Antonio Randazzo
3,
Lelio Mazzarella
1,2 and Filomena Sica
1,2,*
1Dip. di Chimica
‘Paolo Corradini’, Universita ` di Napoli Federico II, Via Cintia, I-80126 Napoli Italia,
2Ist. di
Biostrutture e Bioimmagini, CNR, Via Mezzocannone 16, I-80134 Napoli, Italia and
3Dip. di Chimica delle
Sostanze Naturali, Universita ` di Napoli Federico II, Via D. Montesano 49, I-8013 Napoli, Italia
Received March 1, 2011; Revised June 6, 2011; Accepted June 8, 2011
ABSTRACT
Aptamers are structured oligonucleotides that rec-
ognize molecular targets and can function as direct
protein inhibitors. The best-known example is the
thrombin-binding aptamer, TBA, a single-stranded
15-mer DNA that inhibits the activity of thrombin,
the key enzyme of coagulation cascade. TBA folds
as a G-quadruplex structure, as proved by its NMR
structure. The X-ray structure of the complex
between TBA and human a-thrombin was solved at
2.9-A ˚ resolution, but did not provide details of the
aptamer conformation and the interactions with the
protein molecule. TBA is rapidly processed by nu-
cleases. To improve the properties of TBA, a
number of modified analogs have been produced.
In particular, a modified TBA containing a 50-50
polarity inversion site, mTBA, has higher stability
and higher affinity toward thrombin with respect to
TBA, although it has a lower inhibitory activity. We
present the crystal structure of the thrombin–mTBA
complex at 2.15-A ˚ resolution; the resulting model
eventually provides a clear picture of thrombin–
aptamers interaction, and also highlights the struc-
tural bases of the different properties of TBA and
mTBA. Our findings open the way for a rational de-
sign of modified aptamers with improved potency as
anticoagulant drugs.
INTRODUCTION
Aptamers are single-stranded nucleic acids, both DNA (1)
and RNA (2), which bind molecular targets, including pro-
teins, with high afﬁnity and speciﬁcity. These peculiar fea-
tures are related to a tertiary structure, which presents a
good shape complementarity with the target molecule (3).
Aptamers have been developed for several different ﬁelds
of applications, in particular, as diagnostic and thera-
peutic agents (4). The best-known example is that of the
thrombin-binding aptamer (TBA), a DNA 15-mer consen-
sus sequence, namely 50-GGTTGGTGTGGTTGG-30, dis-
covered in 1992 through the SELEX (Systematic
Evolution of Ligands by Exponential Enrichment) meth-
odology (1) when 10
13 different DNA molecules were
synthesized and screened for thrombin binding.
a-thrombin (thrombin) is a trypsin-like serine protease
that plays a pivotal role in haemostasis. Indeed, it is the
only enzyme capable of catalyzing the conversion of sol-
uble ﬁbrinogen in insoluble ﬁbrin strands and is the most
potent platelet activator. Apart from these procoagulant
functions, thrombin plays also an anticoagulant and anti-
ﬁbrinolytic activity in the presence of thrombomodulin (5).
The capability of inhibiting and regulating thrombin
activity in vivo by synthetic compounds is an important
goal in prevention of thrombosis. The presence on the
thrombin surface of two anion-binding subsites or ‘exo-
sites’, distinct from the catalytic center, makes it a more
discriminating enzyme as compared to other proteases (6).
Exosite I is the recognition site of thrombin physiological
substrate ﬁbrinogen and is also involved in the binding of
leech anticoagulant hirudin, protease-activated receptor-1,
thrombomodulin, factors V and VIII, glycoprotein-1ba
and the acid domain of the serpin heparin cofactor II,
whereas exosite II, which is located on the opposite side
of thrombin, is the binding site of heparin and heparin-
dependent serpins.
It has been shown that TBA is an ‘exosite inhibitor’
(7–9). It has a strong anticoagulant activity in vitro,i ti s
efﬁcient at nanomolar concentration (1) and acts on the
two procoagulant functions of the enzyme: the activation
of ﬁbrinogen and the platelet aggregation. Moreover, it is
able to bind both free and clot-bound thrombin (10,11),
whereas binding to other serum proteins or proteolytic
enzymes is essentially undetectable. The solution structure
of TBA, determined by NMR (12,13), revealed that it
folds in a unimolecular antiparallel quadruplex, with a
chair-like conformation. This conformation is stabilized
by cyclic hydrogen bonding of four guanines (G-tetrads
or G-quartets) and by ions coordination between adjacent
stacks of G-tetrads that are surrounded by two TT loops
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crystal structure of the thrombin–TBA complex was ob-
tained at 2.9-A ˚ resolution (Model 1) (14). The aptamer
adopts a very different quadruplex topology with respect
to the NMR structure. Indeed, the core formed by two
G-quartets is the same in the two models, but structural
differences exist in the way the central bases are con-
nected. In particular, there is a difference concerning the
disposition of the loops with respect to the grooves
(Figure 1A and B). An alternative model of the crystal
structure of the thrombin–TBA complex (Model 2), built
on the basis of the NMR structure of the aptamer, reﬁned
to the same R value as the former Model 1, thus leaving
the doubt on which structure was the correct one (15). In
both models the TBA is sandwiched between two
symmetry-related thrombin molecules and interacts with
exosite I of a thrombin molecule and exosite II of the
second one. In Model 1, the TGT loop is connected to
exosite I and the TT loops are connected to exosite II.
Model 2 shows an inverted pattern of protein–ligand
interactions (15).
The uncertainty between these two models was caused
by the absence of electron density in the region of TT and
TGT loops connecting the G-tetrads. In a more systematic
analysis (16), eight models of the thrombin–aptamer
complex, different for the orientation of the NMR
model of TBA, were tested on the previously used X-ray
diffraction data (14,15). Subtle differences in the crystal-
lographic R-factors and the analysis of the aptamer–
protein interactions indicated that Model 2 was most likely
the correct one. However, due to the missing density in the
loop regions of the aptamer, the details of the ligand–
protein interactions could not be properly addressed.
Moreover, even recent papers still discuss aptamer-
thrombin interactions on the basis of both models (17).
In addition, also the stoichiometry of the complex in
solution has been recently questioned, as two calorimetric
studies suggest either a 2:1 (18) or a 1:1 (19) thrombin to
aptamer molar ratio.
In recent years, several modiﬁed TBA have been pro-
duced and characterized, with the aim to obtain oligo-
nucleotides with improved pharmacological properties,
such as higher stability, higher thrombin afﬁnity, longer
life times in vivo, etc. (3). In particular, the main problem
associated with the use of TBA is a rapid degradation by
nucleases in vivo. Since it has been reported that the inser-
tion of a chain polarity inversion site increases resistance
to endogenous nucleases (20), a modiﬁed aptamer
(mTBA) containing a 50-50 inversion between Thy3 and
Thy4 was produced (21). mTBA presents higher thermal
stability and higher thrombin afﬁnity with respect to its
unmodiﬁed counterpart. The NMR study of mTBA has
revealed that it folds in a chair-like quadruplex structure,
somehow similar to that of TBA (Figure 1C). However,
because of the polarity inversion site, mTBA presents a
(3+1) topology (22–24), with three strands parallel to each
other and the fourth one oriented in the opposite direc-
tion; this topology results in a different syn and anti alter-
nation of the bases within the tetrads and in different
groove sizes. The differences between the two molecules
do not provide a clear justiﬁcation of the different
properties deriving from the inversion site.
Here, we report the crystallographic analysis of the com-
plex between thrombin and mTBA at 2.15-A ˚ resolution.
The higher resolution of the diffraction data, with respect
to that of thrombin–TBA complex, has provided a unique,
well deﬁned model of the complex, which leaves no doubt
on thrombin–aptamer interface. Moreover, the details of
the interactions that the protein molecule makes with
mTBA in comparison to TBA also allows to rationalize
on structural grounds the different behavior of the two
aptamers.
MATERIALS AND METHODS
Crystallization, structure determination and reﬁnement
The thrombin–mTBA complex was prepared and
crystallized as previously described (25). Brieﬂy, mTBA
Figure 1. Schematic illustration of (A) X-ray model of TBA (14), (B) NMR model of TBA (12,13), (C) solution (21) and crystallographic (present
paper) model of the modiﬁed aptamer (mTBA). Black arrows indicate 50!30 polarity of the strands. Black circle in mTBA represents the 50–50
polarity inversion site. Anti and syn guanines are depicted as yellow and blue solids, respectively. Wide and narrow grooves are explicitly indicated in
the three pictures. Red arrows indicate the direction of the proton donors and acceptors in Hoogsteen hydrogen bonds.
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was added to human a-thrombin inhibited by D-
Phe-Pro-Arg-chloromethylketone (PPACK) in KCl
750mM. After extensive washing, the resulting complex
in potassium phosphate 50mM pH 7.1 and KCl 100mM
was crystallized at 20 C using polyethylene glycol 20000
20% w/v, ammonium sulfate 200mM, n-propanol 3% v/v,
sodium acetate 100mM at pH 5.8. The structure was
solved by the molecular replacement method, using the
program AMoRe (26) and the PPACK-inhibited
thrombin (PDB code 1PPB) (27) as a search model. To
avoid bias, inhibitor and water molecules were removed
from the model. The correlation for the highest solution
was 0.59, with an R-factor of 0.36. The starting model was
subjected to few cycles of rigid body reﬁnement with CNS
(28) followed by several cycles of coordinate minimization
and B-factor reﬁnement with CNS. Each run was alter-
nated with manual model building using the program O
(29). Fourier difference maps, calculated with (Fo–Fc) and
(2Fo–Fc) coefﬁcients, showed continuous electron density
in the active site and in proximity of thrombin exosite I.
The analysis of these maps allowed the ﬁtting of PPACK
in the active site, the building of the whole aptamer
molecule, the identiﬁcation of an N-acetyl glucosamine
residue linked to Asn60G of the heavy chain, which is
not present in the search model, and the positioning of
several water molecules. At the end of the reﬁnement,
two strong electron density peaks were assigned to ions:
one, placed near the segment 220–225 of thrombin, was
attributed to a sodium ion, according to previous studies
(30). The second one, placed between the two G-quartets
and almost equidistant from the O6 atoms of the eight
core guanines, was attributed to a potassium ion. The
ﬁnal model has R-factor/Rfree values of 0.196/0.252. The
protein geometry of the reﬁned structure was monitored
using PROCHECK (31) and WHATCHECK (32).
Statistics and parameters of the reﬁnement are given in
Supplementary Table S1. The drawings were prepared
with Pymol (http://pymol.org). The coordinates of the
structure have been deposited in the Protein Data Bank
(Code 3QLP).
Structural analysis of mTBA and thrombin–mTBA
complex
The geometry of the base assembly in mTBA was analyzed
using a program that calculates the least squares plane of
the two tetrads, the root mean square deviation of guanine
atoms from the best planes, the angle that each guanine
residue makes with the best plane of the tetrad to which it
belongs, and the angle between the two G-quartet planes
and their distance along the chain axis.
The network of water molecules bound to mTBA was
identiﬁed with HBPLUS (33) and by visual inspection of
the structure. Unconventional CH   O hydrogen bonds
were identiﬁed using HBAT (34).
Features of the protein–aptamer interface, including
number and types of residues at the interface, and gap
volume index, were calculated using the Protein–Protein
Interaction Server (http://www.bioinformatics.sussex.ac
.uk/protorp/). For comparison, the same parameters
were calculated as average values from a non-redundant
dataset of 25 protein–double-stranded DNA complexes
solved at a resolution better than 2.4A ˚ . The shape com-
plementarity score, Sc, as deﬁned by Lawrence and
Colman (35), was calculated using the CCP4 package
(36), opportunely modiﬁed to include nucleic acid param-
eters. For atomic groups in DNA, radii standard values by
Nadassy et al. (37) were used.
RESULTS
Overall structure
The structure of the complex between thrombin and the
modiﬁed aptamer (mTBA) has been solved at 2.15-A ˚ reso-
lution (Figure 2). Detailed statistics of the reﬁnement are
reported in Supplementary Table S1.
The polypeptide chain of thrombin is very well deﬁned
for the whole heavy chain (residues 16–247) and for resi-
dues 1H–14L of the light chain. All residues in the reﬁned
structure lie within ‘allowed’ regions of the Ramachandran
plot. As expected, the ﬁnal model maintains all the struc-
tural features of the uncomplexed molecule. Indeed, in
comparison to the unbound PPACK-inhibited enzyme
(PDB code 1PPB) (27) the RMSD after the superposition
of all the Ca protein atoms is only 0.67 A ˚ . The largest
deviations are localized in the light chain, at the residues
of the ﬂexible N- and C-terminal tails, whose conform-
ation is usually found to be strongly affected by crystal
packing. Similar results are also obtained when the present
Figure 2. Overall structure of the thrombin–mTBA complex.
Thrombin molecule is represented as cartoon, with heavy chain
colored purple, light chain colored light pink, exosite I colored
orange and exosite II colored cyan. mTBA molecule is represented as
sticks.
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complex with TBA (PDB code 1HAO) (15). In this case,
the slightly larger RMSD of 0.95A ˚ is evenly distributed
along the molecule and is likely related to the signiﬁcantly
lower resolution and quality of the latter structure. For
this reason further comparisons have been done with the
uncomplexed molecule (PDB code 1PPB).
mTBA molecule
The X-ray analysis of mTBA in complex with thrombin
reveals that the molecule folds as a chair-like quadruplex
with two stacked G-quartets, the TGT loop on one side
and the two TT loops on the other side. Because of
the presence of the chain inversion (Supplementary
Figure S1A), mTBA possesses three strands parallel to
each other and the fourth one oriented in the opposite
sense, as also found in the solution structure of free
mTBA (21) (Figure 1C).
Geometrical details of the G-quartet assembly are given
in Supplementary Table S2 in comparison to those derived
from solution structure. For each tetrad, the four guanine
moieties that constitute each quartet are practically
coplanar and their relative orientation and separation
along the chain axis are in close agreement with the
expected values for the p-stacking of aromatic bases. In
comparison to the solution structure of free mTBA (21),
the analysis reveals that in our crystallographic model the
G-tetrads are less distorted from the ideal planar
geometry. Interestingly, the separation of the tetrads in
the former structure is signiﬁcantly larger. In this
context, it should be pointed out that in the crystallo-
graphic structure a potassium ion, which efﬁciently stabil-
izes quadruplex structures (38), is sandwiched between the
two quartets (Supplementary Figure S1B). The ion has a
coordination number of eight and a distorted
antiprismatic geometry, at an average distance of 2.8 A ˚
from the eight O6 atoms. In the reﬁnement of the NMR
structure, the presence of the metal ion was not
contemplated and this may be the reason for the more
compact structure of the two tetrads observed in the
crystal state.
A detailed comparison between the unbound and com-
plexed aptamer is of particular interest as it gives a deeper
insight into the dynamics of the aptamer and the way its
structure modiﬁes to optimize the interaction with the
protein molecule. With respect to free mTBA, the two
TT loops, which form the most extended interacting
surface with the thrombin molecule, move away from
each other (Figure 3A and B) and the hydrogen bond
between Thy4 and Thy13 is lost with the insertion of a
bridging water molecule (Figure 3C and D). These two
bases lie on a plane that stacks on the second G-quartet
formed by Gua2, Gua5, Gua11, Gua14. Furthermore,
Thy3 adopts a conformation that is completely different
in the two models (Figure 3A and B). Interestingly, the
more compact structure of the aptamer caused by the
presence of the potassium ion in between the two tetrads
combined to the binding of TT loops to thrombin, may
also explain modiﬁcations observed in the TGT loop
placed on the other side of the tetrads with respect to
the TT loops. The TGT loop adopts in the crystal struc-
ture a different conformation, which is unlikely caused by
the few and weak packing interactions with a second
thrombin molecule (see below). Gua8 and Thy9, which
in the solution structure stack on the quartet formed by
Gua1, Gua6, Gua10 and Gua15, loose the interaction
with the G-tetrad, become more parallel to each other
and make direct stabilizing interactions (Figure 3A
and B). This conformational change probably determines
the expulsion of Thy7 from the wide groove so that the
base becomes more exposed to the solvent and disordered.
The analysis of mTBA structure highlights some inter-
esting features. Whereas in nucleic acids structures the C8
of purine in anti conformation has been reported to form
weak intraresidue C-H   O interactions with the O5’
(39–41), in mTBA inter-residue contacts between C8 and
O40 are observed (Supplementary Figure S2). A brief ana-
lysis of other quadruplex structures (PDB codes: 2AVH,
1JPQ, 1I34) shows that this type of interaction is not
unusual in antiparallel quadruplex, where guanine residues
with syn and anti conformations alternate along the
strand. On the contrary it is absent in parallel structures
with all anti guanines. This interaction is likely to contrib-
ute to some extent to the stability of the G-quadruplex.
Special attention was devoted to investigating the
nucleotide-water interactions that are decisive for stabil-
ity, dynamics, and recognition. The high resolution of the
diffraction data gives the opportunity to study in details
the organization of the water molecules bound to the
aptamer, particularly in the four grooves. In these
regions, the water molecules arrange themselves in a con-
tinuous network of hydrogen bonds, linking the backbone
and the bases of the quadruplex. In G-quadruplex, water
molecules are preferentially placed close to N2 and C8
atoms of guanines (42–44). Indeed in the modiﬁed
aptamer structure, a conserved network of sequential
N2–water–water–C8 hydrogen bonds is present in the
narrow groove and in one of the two medium grooves; it
connects adjacent strands and involves ﬁve of the eight
core guanines (Gua2, Gua10, Gua11, Gua14, Gua15)
(Supplementary Figure S3). New and less regular
patterns of hydration, involving N2, N3 or backbone
oxygens and a greater number of water molecules
between adjacent strands, are observed in the wide
groove and in the other medium groove. The mTBA
model also reveals new features: the traditional C8–
water–phosphate oxygen network is not predominant
with respect to interactions where water molecules
bridge C8 and oxygen atoms (O40 or O30) of the
backbone or other water molecules.
Thymine bases, being primarily involved in the binding
with thrombin, are less hydrated than guanines. The
non-conventional binding of waters to the C6 atom
observed, for example, for thymines of the quadruplex
of Oxytricha nova telomeric sequence (42) or for all
thymines of B-DNA (45), in the case of mTBA involves
only Thy4. Finally, a water molecule is hydrogen bonded
to the methyl group of Thy12.
This rich pattern of hydration involves both the four
grooves and the three loops and it is likely to play a key
role in maintaining the loop conformation.
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The structure of the complex deﬁnitely shows that mTBA
interacts with thrombin exosite I by its TT loops with a
further contribution of the backbone of Gua2 (Table 1).
The recognition involves primarily the protein residues
Leu65, Arg75, Tyr76, Glu77, Arg77A, Asn78, Ile79,
Ile82. Upon binding, mTBA undergoes to a slight struc-
tural rearrangement, particularly in the TT loops (see
above), whereas the thrombin molecule strictly retains its
original structure (observed in the PPACK-thrombin
structure, PDB code 1PPB), except for the ﬂipping of
the peptide group between Arg77A and Asn78
(Supplementary Figure S4). In the unbound molecule,
these residues are in the second and third position, respect-
ively, of a type I b-turn. In the complex, the turn is con-
verted into a type II b-turn with Asn78 in a La
conformation. The peptide ﬂipping is favored by the pres-
ence of Asn in the third position of the turn, since this
residue is known to populate the La region of the
Ramachandran map (46). This modiﬁcation of the protein
appears to be functional, as it optimizes the contacts with
the bound aptamer: the carbonyl oxygen of Arg77A
points toward the base of Thy13, thus improving the com-
plementarity between the interacting surfaces; moreover,
the guanidium group is salt-bridged to the phosphate of
Gua2 and makes a hydrogen bond with Thy4. Interactions
Figure 3. Comparison between the crystallographic structure (A and C) and the free structure in solution (21) (B and D) of mTBA. (A and B)
Residues that adopt different conformations in the two models are depicted in magenta. (C and D) Thy4-Thy13 pair of mTBA. (C) The bridging
water molecule in the crystallographic structure is also shown.
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hydrophilic (Table 1). Thy3 occupies a hydrophobic patch
lined by Leu65, Ile82 and Tyr76 (Figure 4A) that is in turn
in contact with Thy4 (Figure 4B); Thy12 and Thy13 are in
contact with Asn78 and Ile79. On the other hand,
hydrogen bonds between the guanidium group of Arg75
and Thy4 and Thy13, together with those provided by
Arg77A, contribute substantially to the stabilization of
this TT pair. Thy12 also interacts with Glu77.
Moreover, several water-mediated interactions between
mTBA and thrombin residues (Thr74, Gly69, Gly25,
His71, Lys81, Ser115, Tyr117) have been also identiﬁed.
Interestingly, in the crystal structure mTBA interacts
with a second thrombin molecule by its TGT loop. This
interaction buries a contact area that is less than half of
that involving exosite I (248 A ˚ 2 versus 570 A ˚ 2). In particu-
lar contacts between TGT loop and the second thrombin
molecule are limited to Thy9 that is involved in cation–p
interaction with Arg97 and in a hydrogen bond with
Glu97A, which in turn is hydrogen bonded to Gua15.
These two thrombin residues are external to exosite II
(Figure 5).
Comparison with thrombin–TBA and other protein–DNA
complexes
In order to obtain a deeper characterization of the com-
plex, we calculated several interface parameters, such as
the buried surface area (ASA), the ‘gap volume index’,
number and type of protein interacting residues, the con-
tribution of polar, non-polar and neutral atoms. These
values are given in Table 2 and compared with those
obtained for Model 2 of thrombin–TBA complex (PDB
code 1HAO) (15) and with the mean values obtained by a
non-redundant dataset of 25 protein–DNA complexes.
Interestingly, the thrombin–mTBA interface is much
smaller than that generally found in protein–DNA
complexes, it contains an unusual large number of non-
polar atoms and it is constituted by a number of residues
that have a low propensity to bind nucleic acids, such as
leucine, isoleucine and glutamic acid (47). A remarkable
feature of the interface is its tight packing (Figure 4A), as
judged by the surface complementarity index (Sc) that is
one of the highest observed for protein–DNA complexes.
In particular, with respect to TBA, the chain polarity in-
version causes a better ﬁt of the nucleotide in thrombin
exosite I (Sc value 0.73 versus 0.56) and allows a larger
number of hydrogen bonds to be formed at the interface.
Figure 4. (A) Surface representation of thrombin–mTBA complex. Thrombin molecule is colored purple, mTBA green, Thy3 is marked in cyan and
the hydrophobic cavity lined by Leu65,Tyr76 and Ile82 side chains is marked in orange, (B) hydrogen bonds involving Thy4. Omit Fo Fc electron
density maps (5.0 s level) of Thy4, Arg75 and Arg77A are also shown as example.
Table 1. Interactions between thrombin and mTBA at the most
extended interface
mTBA
residue
Hydrogen bonds Hydrophobic
interaction
Atom Thrombin
residue
Atom Distance
(A ˚ )
Thrombin
residue
Gua2 O2P Arg77A NH1, NH2 3.17, 3.27
Thy3 – – – – Tyr76, Leu65,
Ile82
Thy4 O40 Tyr76 N 2.83 Tyr76
Thy4 O2 Arg75 NH2 3.07
Thy4 O4 Arg77A NH1 2.90
Thy12 N3 Glu77 OE2 2.88 Ile79
Thy13 O4 Arg75 NH1, NH2 3.15, 2.57 Asn78, Ile79
Thy13 O30 Asn78 ND2 2.81
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Aptamers possess several properties that make them very
promising molecules; indeed, thanks to their high afﬁnity
and speciﬁcity toward the target protein, therapeutic
dosing at sub-micromolar levels should be allowed, by
reducing potential non-speciﬁc effects. Furthermore, they
are supposed to be non-immunogenic and antidotes can be
designed to control their pharmacologic activity (48), they
can be completely engineered and possess desirable storage
properties. They are also readily produced and easily
modiﬁed by chemical synthesis. The structural modiﬁca-
tions are generally aimed to increase thermal and nucle-
ases stability, cellular delivery and improve surface
attachment to the target.
Since thrombin is the key enzyme of the coagulation
cascade, it represents an ideal target for anticoagulant
therapeutics and indeed a few years ago the Phase I
clinical trial of TBA was started. Despite this encouraging
scenario, up to now the rational design of new aptamer-
based antithrombotic agents has been hampered by the
absence of a clear knowledge of interactions between
thrombin and TBA, due to the low quality of the diffrac-
tion data used for structure reﬁnement and analysis (16).
In this context, the higher resolution structure of the
complex between thrombin and the modiﬁed aptamer
mTBA is of particular interest, because it allows identify-
ing the molecular details of the protein–nucleotide recog-
nition. The aptamer tightly binds to thrombin exosite I by
its TT loops, through a mix of hydrophobic and polar
interactions, consistently with previous biochemical
studies (8) on TBA. In agreement with the revised inter-
pretation of the crystallographic data on the thrombin–
TBA complex (16), our results on the thrombin–mTBA
complex deﬁnitely identify in the TT loops a general struc-
tural feature for the binding of aptamers to thrombin. In
both cases, these loops act as a pincer-like system that
embraces the protruding region of exosite I (Figure 2).
However, the details of the interactions are different for
the two aptamers (Table 1). Indeed the chain inversion in
mTBA determines the formation of a greater number of
contacts with the enzyme with respect to the unmodiﬁed
nucleotide and more generally, leads to an increased shape
complementarity, as shown by the surface complementar-
ity index Sc (Table 2). These results may well account for
the higher afﬁnity toward thrombin of mTBA as compared
to TBA (18). On the other hand, the interaction between
Thy12 and His71, which is present in the TBA complex
(15), is lost in the case of mTBA. His71 plays a key role in
the recognition of ﬁbrinogen and its interaction with TBA
is considered important for the inhibition of thrombin
clotting activity by the aptamer (8). The position of this
histidine is the same in the two complexes, but the chain
inversion in mTBA causes a subtle reorganization of the
Figure 5. Packing contacts involving mTBA. Thrombin molecules are
represented as cartoon, aptamer molecule as sticks. The symmetry
related thrombin molecule (the symmetry relationship is  x+1/2,
y 1/2,  z+1/2) is colored in blue, with residues interacting with
mTBA marked in cyan and residues belonging to exosite II marked
in yellow. A zoomed vision of the interactions between Thy9 and the
second thrombin molecule is reported in the panel.
Table 2. Protein–DNA interface features
Thrombin–
mTBA
Thrombin–
TBA
(Model 2)
(15)
Protein–
DNA
complexes
a
Sequence segmentation 4 5 7 (4)
 ASA (A ˚ 2) 570 462 1320 (495)
 %ASA 4.8 4.0 13 (7)
Atoms in interface 60 40 122 (51)
Polar atoms contribution
to interface (%)
24.3 25.0 30 (7)
Non-polar atoms contribution
to interface (%)
54.2 38.0 30 (11)
Neutral atoms contribution
to interface (%)
45.5 37.7 40 (9)
Residues in interface (%) 15 12 43 (20)
Polar residues in interface (%) 46.7 58.3 37 (10)
Non-polar residues in
interface (%)
33.3 25.0 28 (9)
Charged residues in
interface (%)
20.0 16.7 35 (9)
Hydrogen bonds 11 2 21 (9)
Hydrogen bonds
(/100A ˚ 2 ASA)
1.9 0.5 1.6 (0.4)
Bridging water molecules 4 0 17 (10)
Bridging water molecules
(/100A ˚ 2 ASA)
0.7 0 1.3 (0.7)
Gap volume (A ˚ 3) 2710 2997 7408 (3050)
Gap volume index (A ˚ ) 2.38 3.49 3.0 (1.0)
Sc 0.73 0.56 0.65 (0.05)
aProperties were calculated from a non-redundant data set of 25
protein–DNA complexes belonging to different protein–structure
families with resolution better than 2.4A ˚ .
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Thy12 (Figure 6A). As result a new salt bridge is formed
between the side chain of Arg77A and the phosphate
oxygen atom of Gua2, which is in close proximity
because of the 3’!5’ inverted polarity of the strand. In
Model 2 TBA backbone is far away from Arg77A, whose
side chain is ﬂipped in the opposite direction. In addition,
the movement of Ile79, which is in close contact with
Thy12, causes in mTBA a displacement of this thymine
away from His71 (Figure 6B). Thus, the greater disponib-
ility of His71 to interact with the ﬁbrinogen could explain
the lower anticoagulant activity of mTBA (18).
A stabilizing interface of the aptamer with exosite II of
a second thrombin molecule was also suggested on the
basis of the crystallographic data on the TBA complex
(14,15). In the mTBA complex, which assembles in the
solid state with a different crystal packing, the surface
contact with exosite I is maintained, whereas there are
no interactions with exosite II. Contacts with other regions
of the protein are in general fewer when compared with
those involving exosite I. On the other hand, although the
association of mTBA with exosite I of thrombin involves a
rather small interface area when compared with those usu-
ally found in other DNA–protein complexes, it is
characterized by an excellent shape complementarity and
a high number of intermolecular interactions, which are
typical for aptamers. These ﬁndings, together with the fact
that in the crystals of both complexes the asymmetric unit
contains one protein molecule and one aptamer, strongly
suggest that thrombin–aptamers complexes have also in
solution a 1:1 stoichiometry, in agreement with the more
recent ITC data (19).
In conclusion, the high-resolution structure of
thrombin–mTBA complex here reported clariﬁes several
questions regarding thrombin–aptamers interaction. It
deﬁnitely establishes the way in which the aptamer inter-
acts with thrombin and allows a properly characterization
of the contact surface between the two molecules.
Moreover, the results highlight the structural bases of
the different properties of TBA and mTBA, and in par-
ticular their different anticoagulant activities.
The X-ray analysis conﬁrms the general folding (‘3+1’
arrangement) found by NMR studies of free mTBA, with
three strands parallel to each other and the forth one
oriented in the opposite sense. This ﬁnding further
enforces the idea that the ‘3+1’ core topology is not to
be considered an anomaly, but rather a robust
G-quadruplex scaffold, on which new modiﬁcations can
be inserted (22–24). Indeed, starting from the mTBA
structure, it is possible to design modiﬁed aptamers that
preserve both stability against nucleases and high afﬁnity
toward thrombin characteristic of mTBA, and in addition,
possess a more effective antithrombotic action. A prelim-
inary modeling suggests that modiﬁcations in the Thy12–
Thy13 loop could restore the interaction, active in the
thrombin–TBA complex, of the aptamer with His71, a
key residue for the recognition between the ﬁbrinogen
and exosite I. In particular, chemical modiﬁcation of
Thy12 could create new contacts with this protein
residue thus improving the anticoagulant action of the
aptamer. Experiments are in progress along this line.
More in general, the present investigation provides the
scientiﬁc community with an enhanced structural and con-
formational knowledge that will serve as a platform for a
rational design of modiﬁed aptamers for use in anticoagu-
lant therapies.
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Figure 6. Superposition of thrombin–mTBA (purple) on the Model 2 of thrombin–TBA (PDB code 1HAO) (15) (orange): (A) interactions between
TBA Thy12 and His71 and between mTBA Gua2 and Arg77A, (B) displacement of mTBA Thy12 from His71.
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